PMID- 36547992
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221227
IS  - 2305-6320 (Print)
IS  - 2305-6320 (Electronic)
IS  - 2305-6320 (Linking)
VI  - 9
IP  - 12
DP  - 2022 Nov 22
TI  - The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 
      Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study.
LID - 10.3390/medicines9120059 [doi]
LID - 59
AB  - Background: The incidence and risk of urinary tract infection (UTI) in patients 
      with type 2 diabetes mellitus (T2DM) who use sodium glucose co-transporter-2 
      (SGLT2) inhibitors are still controversial. Therefore, this study aimed to 
      investigate the incidence and risk factors of using SGLT2 inhibitors, 
      particularly in Thai patients. Methods: Electronic medication records of all 
      patients, who started the treatment of T2DM between 1 January 2019 and 30 June 
      2021 at a tertiary hospital in Thailand, were reviewed. The patients were divided 
      into SGLT2 inhibitor and non-SGLT2 inhibitor groups to compare the incidence of 
      UTI. Results: The overall incidence rate of UTI was 33.49% in the SGLT2 inhibitor 
      group and 11.72% in the non-SGLT2 inhibitor group. The incidence rates of UTI 
      were not different between dapagliflozin and empagliflozin treatment (34.00% and 
      33.03%, respectively). Patients treated with SGLT2 inhibitors had a 3.70 higher 
      risk of UTI compared with those treated with non-SGLT2 inhibitors (95%CI 
      2.60-5.29). Moreover, the significant risk factors for UTI found in this study 
      were gender, age, and occupation. Conclusions: This study highlighted the high 
      incidence of UTI in patients using dapagliflozin and empagliflozin compared with 
      non-SGLT2 inhibitors. Additionally, patients of female gender and older age had a 
      significantly higher risk of UTI when treated with SGLT2 inhibitors, whereas 
      those with permanent jobs had a lower risk.
FAU - Uitrakul, Suriyon
AU  - Uitrakul S
AUID- ORCID: 0000-0003-3943-4896
AD  - Department of Pharmaceutical Care, Walailak University, Tha Sala, Nakhon Si 
      Thammarat 80160, Thailand.
FAU - Aksonnam, Krittika
AU  - Aksonnam K
AD  - Department of Pharmaceutical Care, Walailak University, Tha Sala, Nakhon Si 
      Thammarat 80160, Thailand.
FAU - Srivichai, Pimchanok
AU  - Srivichai P
AD  - Department of Pharmaceutical Care, Walailak University, Tha Sala, Nakhon Si 
      Thammarat 80160, Thailand.
FAU - Wicheannarat, Sorawit
AU  - Wicheannarat S
AD  - Department of Pharmaceutical Care, Walailak University, Tha Sala, Nakhon Si 
      Thammarat 80160, Thailand.
FAU - Incomenoy, Supatcha
AU  - Incomenoy S
AUID- ORCID: 0000-0002-2789-6121
AD  - Department of Pharmaceutical Care, Walailak University, Tha Sala, Nakhon Si 
      Thammarat 80160, Thailand.
LA  - eng
GR  - N/A/Walailak University/
PT  - Journal Article
DEP - 20221122
PL  - Switzerland
TA  - Medicines (Basel)
JT  - Medicines (Basel, Switzerland)
JID - 101671069
PMC - PMC9785475
OTO - NOTNLM
OT  - incidence
OT  - risk factor
OT  - sodium glucose co-transporter-2 inhibitor
OT  - type 2 diabetes mellitus
OT  - urinary tract infection
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/23 06:00
MHDA- 2022/12/23 06:01
PMCR- 2022/11/22
CRDT- 2022/12/22 11:42
PHST- 2022/11/03 00:00 [received]
PHST- 2022/11/15 00:00 [revised]
PHST- 2022/11/21 00:00 [accepted]
PHST- 2022/12/22 11:42 [entrez]
PHST- 2022/12/23 06:00 [pubmed]
PHST- 2022/12/23 06:01 [medline]
PHST- 2022/11/22 00:00 [pmc-release]
AID - medicines9120059 [pii]
AID - medicines-09-00059 [pii]
AID - 10.3390/medicines9120059 [doi]
PST - epublish
SO  - Medicines (Basel). 2022 Nov 22;9(12):59. doi: 10.3390/medicines9120059.